SCHEMBL14101482

SCHEMBL14101482

c1ccc2c(c1)sc1cc(-c3ccc4ccc5c(-c6ccc7sc8ccc(-c9ccc%10ccc%11c(-c%12ccc%13c(c%12)sc%12ccccc%12%13)ccc%12ccc9c%10c%12%11)cc8c7c6)ccc6ccc3c4c65)ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GPR3 P46089 1/20 0.42
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALOX5 P09917 1/20 0.38
CYP1A2 P05177 3/20 0.35
MAOA P21397 2/20 0.34
ERBB2 P04626 1/20 0.34
FYN P06241 1/20 0.34
ACHE P22303 1/20 0.34
AHR P35869 1/20 0.34
MAOB P27338 1/20 0.34
PTPN7 P35236 1/20 0.33
DUSP3 P51452 1/20 0.33
PTPN12 Q05209 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14101479 0.97 GPR3 (0.45) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL14101565 0.97 GPR3 (0.45) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21190587 0.95 MAPT (0.47) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL14101487 0.93 GPR3 (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL14101522 0.93 CYP1A2 (0.44) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL14101524 0.93 GPR3 (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL13682521 0.91 GPR3 (0.40) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL21346582 0.91 CYP1A2 (0.45) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL13682482 0.90 GPR3 (0.39) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL13658621 0.89 ALDH1A1 (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080166594-A1 BENZOTHIOPHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE MAKING USE OF THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2008-07-10 US disclosed
US-20080166594-A1 BENZOTHIOPHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE MAKING USE OF THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080166594-A1 BENZOTHIOPHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE MAKING USE OF THE SAME CYBA, BPNT1, TYR MAPT 226/4885ALDH1A1 70/4885HPGD 2873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.